Nor surprising, Gene Therapy is on the nose across all indications - FDA met with Big Pharma a few months back to discuss safety issues.
Pfizer, Sarepta - and Roche's investment in Sarepta's GT - won't see commercialization anytime soon.
First we had Sarepta's "unlucky randomization" excuse in January, now we Pfizer excluding segments of DMD population.
A set back for the DMD community for sure....BUT...a great opportunity for ANP to add a few hundred mill to their partnership agreement..
.
- Forums
- ASX - By Stock
- Where others have failed will Atl1102 succeed ?
Nor surprising, Gene Therapy is on the nose across all...
-
- There are more pages in this discussion • 709 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.2¢ |
Change
0.001(1.23%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.2¢ | 8.2¢ | 8.2¢ | $47.28K | 576.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 144357 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 104529 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 144357 | 0.081 |
5 | 106752 | 0.080 |
2 | 212658 | 0.078 |
2 | 85000 | 0.076 |
4 | 206988 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 104529 | 2 |
0.083 | 214000 | 1 |
0.084 | 67142 | 2 |
0.085 | 91364 | 3 |
0.086 | 106100 | 2 |
Last trade - 13.51pm 12/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |